A股異動丨華北製藥(600812.SH)再創上市以來新高 重組人源抗狂犬病毒單抗注射液被納入擬優先審評品種公示名單
格隆匯8月6日丨華北製藥(600812.SH)漲4.76%,報19.6元,股價再創上市以來新高,總市值319.6億元。華北製藥昨晚公告,公司子公司新藥公司的重組人源抗狂犬病毒單抗注射液8月5日被國家藥品審評中心納入擬優先審評品種公示名單,公示期7日。重組人源抗狂犬病毒單抗注射液(rhRIG)是新藥公司自主創新項目,被列為國家“重大新藥創制”科技重大專項品種。目前,國內尚無重組抗狂犬病毒單抗藥物上市銷售。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.